News

Pharmavite announces two executive appointments: CMO and VP operations

BY Michael Johnsen

NORTHRIDGE, Calif. — Pharmavite on Monday named Etienne Patout (left) as its new chief marketing officer and Brett Buatti (right) as VP operations.
 
"These key appointments come at an important time for Pharmavite and I am certain that both Etienne and Brett's leadership qualities and relevant experience will help drive the company to continued success over the coming years," stated Connie Barry, CEO and board chair Pharmavite. "Etienne brings to Pharmavite a deep and broad understanding of the key tenets of consumer marketing while Brett has proven expertise in operations and supply chain management."
 
As new chief marketing officer, Patout comes to Pharmavite with nearly 20 years of experience within the CPG industry. Most recently, he served as general manager and VP for wholesome snacks at the Kellogg Co. Patout also previously worked at Kraft Foods where he was responsible for a number of key brand portfolios and gained recognition for being a business leader for reinvention and innovation. Patout received his Master of Business Administration from the Carroll School of Management at Boston College. He received his Bachelor of Science in Chemical Engineering from Louisiana State University. He also served as an officer in the U.S. Air Force.
 
Buatti has worked at a number of consumer product companies including General Mills, Dole Food Company, Campbell Soup Company and most recently VP of manufacturing at NBTY. Brett received his Bachelor of Science in Biochemical Engineering and a Bachelor of Arts in Engineering Sciences with a Minor in Economics from Dartmouth College. He also attended a joint program at Thayer School of Engineering and Tuck School of Business at Dartmouth where he earned a Masters of Engineering Management. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Female Health Co. names new EVP global operations

BY Michael Johnsen

CHICAGO — The Female Health Co. on Monday announced that Martin Tayler will join the company's management team as EVP global operations.  
 
Prior to joining the Female Health Company, Tayler had a career in medical device operations leadership with SSL International, a manufacturer of healthcare products under the Durex and Dr Scholl's brands among others, and later with Reckitt Benckiser Group, a consumer health and hygiene company. During his tenure with SSL and Reckitt Benckiser, Tayler was responsible for a variety of operations, functions and facilities in various countries, including oversight of the design, construction and ultimate operation of one of the world's largest condom manufacturing facilities in China.
 
The company also announced that Michael Pope will retire from his position as VP, U.K. and Malaysian Operations. Following his retirement, Pope will continue his affiliation with the company as a Consultant.
 
"We consider ourselves extremely fortunate that Martin is joining the FHC leadership team," stated Karen King, president and CEO FHC. "We believe his extensive global operations leadership experience and knowledge of relevant markets and products will contribute greatly to the future success of our company. I would also like to acknowledge and sincerely thank Mike Pope for his invaluable contributions to the company over the past 24 years. We are delighted that Mike will continue to be a part of our advisory team going forward."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Lupin signs deal to distribute Salix Pharmaceuticals’ gastroenterology products in Canada

BY Michael Johnsen

BALTIMORE — Lupin Limited and Salix Pharmaceuticals on Friday announced that they have entered into a definitive distribution agreement under which Salix has granted Lupin the exclusive right to market, distribute and sell certain Salix products in Canada. 
 
This includes immediate rights to distribute Zaxine (rifaximin) 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older, and Relistor subcutaneous injection for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. 
 
Additionally, the agreement includes future dosage forms, strengths and indications for such products. Under the agreement, Lupin also has the option to exclusively market, distribute and sell other gastroenterology products in Salix’s Canadian pipeline once approved by Health Canada.
 
Lupin will promote the Salix products through its own sales force in Canada. Lupin is in the process of establishing its Canadian presence and the addition of this significant product portfolio opens up growth opportunities for the future. Zaxine and Relistor are first-in-class treatments for their respective disorders and are important treatment options for physicians and their patients, not only in the United States, but now in Canada.
 
Under the terms of the agreement, Salix will receive an upfront payment and distribution fees, and is eligible for additional pre-commercial and sales milestone payments. Salix will supply the products to Lupin under separate supply agreements.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES